Description
A-108 Belgian multicenter study into von Willebrand Disease (B-Will Study): First results
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: A-108 Belgian multicenter study into von Willebrand Disease (B-Will Study): First results
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in melanoma
€3.03 Add to cart -
Article: Highlights in melanoma
€3.03 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart
Reviews
There are no reviews yet.